اكتشاف تطوير مثبتات الليباز المعوية
مراجع

↑  Guerciolini, R., Mode of action of orlistat. International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity, 1997. 21: p. S12-23.
↑  "All centralized human medicinal product by ATC code". Public Health. European Commission. مؤرشف من الأصل في 2019-04-09. اطلع عليه بتاريخ 2016-10-01.
1 2 3 4 5  Lunagariya, N.A., et al., Inhibitors of pancreatic lipase: state of the art and clinical perspectives. EXCLI Journal, 2014. 13: p. 897-921.
1 2 3  Bai, T., et al., Operon for biosynthesis of lipstatin, the beta-lactone inhibitor of human pancreatic lipase. Applied and Environmental Microbiology, 2014. 80(24): p. 7473-7483.
1 2  Purohit, V.C., et al., Practical, Catalytic, Asymmetric Synthesis of β-Lactones via a Sequential Ketene Dimerization/Hydrogenation Process:  Inhibitors of the Thioesterase Domain of Fatty Acid Synthase. The Journal of Organic Chemistry, 2006. 71(12): p. 4549-4558.
1 2 3  Medeiros-Neto, G., A. Halpern, and C. Bouchard, Progress in Obesity Research: 9. Orlistat in the treatment of obesity, ed. A. Halpern. 2003: Food & Nutrition Press.
1 2 3  Birari, R.B. and K.K. Bhutani, Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discovery Today, 2007. 12(19–20): p. 879-889.
1 2  Heck, A.M., J.A. Yanovski, and K.A. Calis, Orlistat, a New Lipase Inhibitor for the Management of Obesity. Pharmacotherapy, 2000. 20(3): p. 270-279.
1 2  Schaefer, B., Natural Products in the Chemical Industry. 2015: Springer Berlin Heidelberg.
↑  Pommier, A., J.-M. Pons, and P.J. Kocienski, The First Total Synthesis of (-)-Lipstatin. The Journal of Organic Chemistry, 1995. 60(22): p. 7334-7339.
1 2 3  Wilding, J.P.H., Pharmacotherapy of Obesity. Intestinal lipase inhibitors, ed. J.P.H. Wilding. 2008: Birkhäuser Basel.
↑  "Summary of Product Characteristics" (PDF). Xenical. European Medicines Agency. 19 ديسمبر 2013. مؤرشف من الأصل (PDF) في 2018-06-19. اطلع عليه بتاريخ 2016-10-01.
↑  "Questions and Answers about FDA's Initiative Against Contaminated Weight Loss Products". U.S Food And Drug Administration. U.S. Department of Health and Human Services. مؤرشف من الأصل في 2019-04-23. اطلع عليه بتاريخ 2016-10-01.
1 2  Bryson, A., S. de la Motte, and C. Dunk, Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. British Journal of Clinical Pharmacology, 2009. 67(3): p. 309-315.
1 2  Al-Suwailem, A., et al., Safety and Mechanism of Action of Orlistat (Tetrahydrolipstatin) as the First Local Antiobesity Drug. Journal of Applied Sciences Research, 2006. 2(4): p. 205-208..
↑  Bray, G.A., L.S. University, and D. Ryan, Overweight and the Metabolic Syndrome: From Bench to Bedside. Ectopic Fat and the Metabolic Syndrome, ed. F.G.S. Toledo and D.E. Kelley. 2007: Springer US.
1 2 3  Padwal, R., Cetilistat, a new lipase inhibitor for the treatment of obesity. Current Opinion in Investigational Drugs, 2008. 9(4): p. 414-421.
↑  Gras, J., Cetilistat for the treatment of obesity. Drugs Today (Barc), 2013. 49(12): 755-9.
1 2  Flavin, R., et al., Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol, 2010. 6(4): p. 551-562.
↑  Richardson, R.D., et al., Synthesis of Novel β-Lactone Inhibitors of Fatty Acid Synthase. Journal of medicinal chemistry, 2008. 51(17): p. 5285-5296.
↑  Fako, V.E., J.-T. Zhang, and J.-Y. Liu, Mechanism of Orlistat Hydrolysis by the Thioesterase of Human Fatty Acid Synthase. ACS Catalysis, 2014. 4(10): p. 3444-3453.
↑  R. Pandey, P., et al., Anti-Cancer Drugs Targeting Fatty Acid Synthase (FAS). Recent Patents on Anti-Cancer Drug Discovery, 2012. 7(2): p. 185-197.
↑  Vaclavik, V., & Christian, E. W. (2007). Essentials of Food Science: Springer New York.
↑  Chow, B. P. C., Shaffer, E. A., & Parsons, H. G. (1990). Absorption of triglycerides in the absence of lipase. Canadian Journal of Physiology and Pharmacology, 68(4), 519-523. doi:10.1139/y90-074
1 2 3  Müller, G. and S. Petry, Lipases and Phospholipases in Drug Development: From Biochemistry to Molecular Pharmacology. Physiology of Gastrointestinal Lipolysis and Therapeutical Use of Lipases and Digestive Lipase Inhibitors. 2006: Wiley.
1 2 3 4 5  Christophe, A.B. and S. DeVriese, Fat Digestion and Absorption. Enzymatic Aspects of Fat Digestion in the Gastrointestinal Tract, ed. R.-D. Duan. 2000: AOCS Press.
↑  Johnson, L.R., Gastrointestinal Physiology. Digestion and absorption of nutrients. 2013: Elsevier Mosby.
↑  Mansbach, C.M., P. Tso, and A. Kuksis, Intestinal Lipid Metabolism. Molecular Mechanisms of Pancreatic Lipase and Colipase, ed. M.E. Lowe. 2011: Springer US.
↑  Shahidi, F., Nutraceutical and Specialty Lipids and their Co-Products. StructureRelated Effects on Absorption and Metabolism of Nutraceutical and Specialty Lipids. 2006: CRC Press.
↑  Christophe, A.B. and S. DeVriese, Fat Digestion and Absorption. Effects of Triacylglycerol Structure on Fat Absorption, ed. C.-E. Høy and H. Mu. 2000: AOCS Press.
↑  Yadav, J.S., et al., Stereoselective synthesis of (−)-tetrahydrolipstatin via a radical cyclization based strategy. Tetrahedron Letters, 2006. 47(26): p. 4393-4395.
↑  Bodkin, J.A., E.J. Humphries, and M.D. McLeod, The Total Synthesis of (–)-Tetrahydrolipstatin. Australian journal of chemistry, 2003. 56(8): p. 795-803.
↑  Christophe, A.B. and S. DeVriese, Fat Digestion and Absorption. The Role of Dietary Fat in Obesity and Therapy with Orlistat, ed. A. Golay. 2000: AOCS Press.
↑  "Orlistat". PubChem Compound Database. National Center for Biotechnology Information. مؤرشف من الأصل في 2019-12-01. اطلع عليه بتاريخ 2016-10-01.
↑  "Cetilistat". PubChem Compound Database. National Center for Biotechnology Information. مؤرشف من الأصل في 2019-08-07. اطلع عليه بتاريخ 2016-10-01.
بوابة صيدلة